No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress
Reshaping the future of patient care
ECOG-ACRIN BY THE NUMBERS
Loading Quotes...
Announcements
Registration for the Fall 2019 Group Meeting will open by late August. Email announcements will circulate when registration opens.
The CRA Core Committee is offering limited travel assistance to the Fall 2019 Group Meeting More Here
Call for Abstracts: Young investigators interested in presenting your research at the Fall 2019 Group Meeting may submit an abstract now Apply Here
Don’t miss the June 2019 Newsletter
Like what you’re reading? We want your feedback! Please take a two-minute newsletter Readership Survey
ComboMATCH concept sheets are being accepted until further notice More Here
NEW! Did you know there is a new TMIST newsletter? More Here
Latest News
The results of leukemia trial E1912 are published in The New England Journal of Medicine. Tait Shanafelt, MD (Stanford University) and colleagues report that treatment with the combination of ibrutinib and rituximab is superior to standard treatment for patients 70 years of age or younger, with chronic lymphocytic leukemia (CLL) More Here
The Journal of Clinical Oncology has published the results of the ACRIN 6685 trial. Val J. Lowe, MD (Mayo Clinic) and colleagues report that surgical planning for head and neck cancer benefits from FDG-PET/CT, especially in patients who are clinically node-negative More Here
San Antonio Breast Cancer Symposium honors ECOG-ACRIN vice chair Joseph A. Sparano, MD with its prestigious William L. McGuire Memorial Lecture Award More Here
TMIST
Amy Curtis, MD (Spartanburg Medical Center): Women are intrigued by the many questions asked in TMIST Conversation with The Cancer Letter
TAILORx
- ASCO updates guidelines for early breast cancer based on TAILORx, MINDACT trials News Article
- TAILORx data guides adjuvant therapy in younger breast cancer patients Press Release
- The New England Journal of Medicine publishes analysis of a pre-specified secondary analysis that adds new information to the original TAILORx findings NEJM Article
- “The Precision of Evidence Needed to Practice “Precision Medicine” NEJM Accompanying Editorial
- Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score® test in node-negative breast cancer Press Release
- One Year Post-TAILORx: Attitudes Shift and Questions Linger in Breast Cancer Recurrence Testing GenomeWeb (requires free registration)
- Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers, by Harold J. Burstein, MD, PhD CancerNetwork
- New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer The ASCO Post
NCI-MATCH
- Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations Press Release
- Keith Flaherty, MD, ECOG-ACRIN study chair, comments on targeted drugs in an article on basket trials published in Xconomy National
E2810
- Final results show no benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Press Release
- ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma who have no Evidence of Disease Following Metastasectomy – Medical Oncologist Perspective UroToday
E3A06
- Final results demonstrate that lenalidomide reduces the risk that precancer myeloma will progress to overt multiple myeloma in high-risk individuals Press Release
E1609
- Low-Dose Ipilimumab Demonstrates Overall Survival Advantage Over High-Dose Interferon-alpha2b in Resected High-Risk Melanoma ASCO Daily News
Group Meeting Highlights
© 2019 ECOG-ACRIN Cancer Research Group. All rights reserved. | Disclaimer